[PDF] Top 20 Factores de movilidad de una comunidad internacionalizada

... Erectile dysfunction is a self-reported condition by the patients and the results of different treatment modalities are also self-evaluated (Hatzimouratidis and Hatzichristou ...ED treatment ... See full document

... the clinical trials are dose-dependent and consistent with the vasodilatatory effect of PDE-5 ...common treatment-emergent adverse events were headache (15%, 12%, 5% respectively), dyspepsia (8%, 7%, 1% ... See full document

... of erectile function were triggered in the late 1980s, with the introduction of intracavernosal injections of vasoactive drugs, followed by therapy with oral agents to safely and effectively treat ... See full document

... 40-70. Sildenafil offers the first orally effective symptomatic treatment of ...Oral sildenafil therapy, while effective in circumventing the cause of ED, provides only short-term symptomatic relief ... See full document

... ED treatment according to patient-specific sex-life ...the treatment of DM-associated ED as other ...its clinical properties, udenafil can be a daily-dosing option for the treatment of ED, as ... See full document

... UK369003 is a PDE5 inhibitor that has been more stud- ied for its effect on lower urinary symptoms than on ED. JNJ-10280205 and JNJ-10287069 are new novel, potent, and selective PDE5 inhibitors that display superior ... See full document

... for evidence of any unwanted ...trial. Clinical assessment was for erectile response and vital ...gel. Clinical erections were scored as 1, no effect; 2, tumescence without rigidity; 3, ... See full document

... of erectile dysfunction, be 18 years or older, be in a heterosexual relationship for at least six months and be able to give written ...for erectile dysfunc- tion and known history of retinitis ... See full document

... whose primary mechanism of action is the antagonism of certain receptors, such as dopamine D2 and serotonin 5-hydroxytryptamine (5HT) receptor 2A. Iloperidone was recently approved in the US for treating schizophrenia, ... See full document

... The physician's decision on the choice of an antiepi- leptic drug for a child with focal-onset seizures is largely dependent on the patient characteristics and on literature about ef fi cacy and safety pro fi les of these ... See full document

... the treatment and prophylaxis of fusariosis in adults, although the clinical response to these drugs were merely ...antifungal treatment in patients ... See full document

... early-phase clinical trials, providing level 3 evidence of its potential in the treatment of hematological ...Substantial evidence indi- cates that obatoclax mesylate can be safely ... See full document

... controlled clinical trials, due to the introduction of biologic agents, especially ...all clinical guidelines, even though evidence of their efficacy is ... See full document

... of clinical response to each available mechanism of action, with the aim to drive the management of the disease toward a personalized approach according to the concept of precision ...the treatment of RA ... See full document

... the treatment of metastatic breast ...several clinical trials have shown that the combination of bevacizumab with a taxane can improve disease-free survival but does not prolong overall ...current ... See full document

... aggressive treatment of this ...for treatment when it becomes ...the treatment of medullary and anaplastic thyroid cancers although the numbers of patients with these subtypes is too small to draw ... See full document

... tubular dysfunction over time (at 52 weeks: hazard ratio [HR] adjusted = ...renal dysfunction, some patients may require tenofovir dose adjustment; if so, Atripla needs to be replaced with its individual ... See full document

... Abstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Signifi cant improvements in the sexual lives of these couples have been achieved with the introduction of ... See full document

... Thirty-one patients (86%) achieved a complete hematologic response. Only two patients experienced disease progression: one of whom carried the imatinib resistance mutation, T315I, which was also associated with ... See full document

... with evidence of response but at high risk of further early recurrence, patients were randomized to receive either nintedanib 250 mg (n = 43) or placebo (n = 40), bid, continu- ously for 36 ... See full document